Five things to know about Trump’s FDA lead pick Gottlieb March 24, 2017 By Karen Appold On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick. Opinion: More industry-stakeholders play blame game for high drug costs March 23, 2017 By Devon Herrick PhD Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs. Payers to pharma: Here’s what we’re missing in hep C drugs February 17, 2017 By Tracey Walker A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment. Top challenges in cancer care January 14, 2017 By Tracey Walker Cancer drug costs remain the most critical challenge in care, among other things. How state-mandated formularies impact costs November 12, 2016 By Tracey Walker Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary. Copay assistance programs: Managed care pros and cons Do copay assistance program offer a long-term solution for patients? Experts weigh in. Three ways to rein in drug costs regardless of who becomes president October 13, 2016 By Marc O'Connor It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation. Drug pipeline developments: Alopecia areata and atopic dermatitis Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost. Nearly half of BCBS members discontinue this RA drug after 1 year October 06, 2016 By Tracey Walker Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.